Oncologic Implications of Chronic Hepatitis C Virus Infection
Journal of Oncology Practice · 2019-12 · 15 (12) · 629-637
DOI: 10.1200/jop.19.00370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Practice, 2019-12. Verfasst von Jessica P Hwang und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Chronic hepatitis C virus (HCV) infection increases the risk for several types of cancer, including hepatocellular carcinoma (HCC) and B-cell non-Hodgkin lymphoma, as primary and second primary malignancies. HCV-infected patients with cancer, particularly those undergoing anticancer therapy, are at risk for development of enhanced HCV replication, which can lead to hepatitis flare and progression of liver fibrosis or cirrhosis. Risk factors for HCV infection include injection drug use, blood transfusion, or solid organ transplantation before 1992, receipt of clotting factor concentrates before 1987, long-term hemodialysis, chronic liver disease, HIV positivity, and occupational exposure. Widely available direct-acting antivirals are highly effective against HCV and well tolerated. Identification of HCV-infected individuals is the essential first step in treatment and eradication of the infection. One-time screening is recommended for persons born from 1945 to 1965; screening is also recommended for persons with risk factors. Recently, a public health recommendation has been drafted to screen all adults age 18 to 79 years. Two oncology organizations recommend screening all patients with hematologic malignancies and hematopoietic cell transplant recipients, and a recently published multicenter prospective study supports universal HCV screening for all patients with cancer. HCV screening entails testing for anti-HCV antibodies in serum and, when results are positive, HCV RNA quantitation to confirm infection. Direct-acting antiviral therapy eradicates HCV in almost all cases. Virologic cure of HCV prevents chronic hepatitis and progression to liver fibrosis or cirrhosis. HCV eradication also decreases the risk of developing HCV-associated primary and second primary malignancies, and it may allow HCV-infected patients access to important cancer clinical trials. Patients with HCV-related cirrhosis require lifelong surveillance for HCC, even after viral eradication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, TX.
- University of Wisconsin Carbone Cancer Center, Madison, WI.
- University of Wisconsin School of Medicine and Public Health, Madison, WI.
- American Society of Clinical Oncology, Alexandria, VA.
Zitieren
APA
Hwang, J. P., LoConte, N. K., Rice, J. P., Foxhall, L. E., Sturgis, E. M., Merrill, J. K., Torres, H. A., & Bailey, H. H. (2019). Oncologic Implications of Chronic Hepatitis C Virus Infection. Journal of Oncology Practice, 15(12), 629-637. https://doi.org/10.1200/jop.19.00370
Vancouver
Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, et al. Oncologic Implications of Chronic Hepatitis C Virus Infection. Journal of Oncology Practice. 2019;15(12):629-637. doi:10.1200/jop.19.00370
BibTeX
@article{Hwang2019,
author = {Hwang, Jessica P and LoConte, Noelle K and Rice, John P and Foxhall, Lewis E and Sturgis, Erich M and Merrill, Janette K and Torres, Harrys A and Bailey, Howard H},
title = {Oncologic Implications of Chronic Hepatitis C Virus Infection},
journal = {Journal of Oncology Practice},
year = {2019},
volume = {15},
number = {12},
pages = {629--637},
doi = {10.1200/jop.19.00370}
}
EUVIMED